GUNSHOT INJURIES TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Increasing incidence of traumatic injury is expected to augment growth of the gunshot injuries treatment market

Traumatic injury remains a persistent and significant public health problem, which poses as a major factor driving demand for gunshot injuries treatment. According to the Centers for Disease Control and Prevention, around 84,000 gun-shot related injuries and around 2 million knife related injuries were recorded in 2013, globally. The injuries cause deep hemorrhagic wounds, which are characterized by profuse bleeding from the ruptured blood vessels. Stats released by the Food and Drug Administration,2015, has predicted that the deaths due to gunshot or traumatic injuries is expected to account for 30-40% of civilian deaths, often before the patient reaches the hospital. It further revealed that the innovative FDA approved Xstat would possibly make a difference to prevent mortality, if made available to the emergency personnel to prevent delay in care, as hospital care cannot be accessed immediately. North America is expected to hold a dominant position in the gunshot injuries treatment market, attributed to the availability of advanced and FDA approved products such as sponge-filled syringe and bandages. According to data published in Trauma Reports in 2012, penetrating trauma is the second major cause of injury-related deaths, with an around 60,000 - 80,000 occurrence rate of nonfatal gunshot, in the U.S.

FDA approval of the gunshot injuries treatment products is a prominent factor fueling the gunshot injuries treatment market

Advancements in medicine and technology help prevent the mortality rate associated with gunshot injuries, thus augmenting the demand for these preventive and efficient products. Xstat is the only gunshot wound management device, which is extensively used on battlefields, globally. XStat was manufactured by RevMedx and approved by the FDA in April, 2014, to plug up life-threatening wounds. Furthermore, the launch and availability of these devices is expected to propel the market in Asia Pacific and Europe. The clearance of the Xstat 30 for gunshot injury treatment expands the device’s indication for use for adults and adolescents in the general population, thereby facilitating the market growth. XStat 30 was FDA-approved in December 2015, for use for patients with high life-threatening risk, suffering from immediate and severe hemorrhagic shocks when definitive care at an emergency care facility cannot be achieved within minutes.